Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

Ayman Saad; Alison Loren; Javier Bolaños-Meade; George Chen; Daniel Couriel; Antonio Di Stasi; Areej El-Jawahri; Hany Elmariah; Sherif Farag; Krishna Gundabolu; Jonathan Gutman; Vincent Ho; Rasmus Hoeg; Mitchell Horwitz; Joe Hsu; Adetola Kassim; Mohamed Kharfan Dabaja; John Magenau; Thomas Martin; Marco Mielcarek; Jonathan Moreira; Ryotaro Nakamura; Yago Nieto; Cameron Ninos; Caspian Oliai; Seema Patel; Brion Randolph; Mark Schroeder; Dimitrios Tzachanis; Asya Nina Varshavsky-Yanovsky; Madhuri Vusirikala; Frankie Algieri; Lenora A. Pluchino

doi:10.6004/jnccn.2023.0007

Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

Ayman Saad, Alison Loren, Javier Bolaños-Meade, George Chen, Daniel Couriel, Antonio Di Stasi, Areej El-Jawahri, Hany Elmariah, Sherif Farag, Krishna Gundabolu, Jonathan Gutman, Vincent Ho, Rasmus Hoeg, Mitchell Horwitz, Joe Hsu, Adetola Kassim, Mohamed Kharfan Dabaja, John Magenau, Thomas Martin, Marco MielcarekJonathan Moreira, Ryotaro Nakamura, Yago Nieto, Cameron Ninos, Caspian Oliai, Seema Patel, Brion Randolph, Mark Schroeder, Dimitrios Tzachanis, Asya Nina Varshavsky-Yanovsky, Madhuri Vusirikala, Frankie Algieri, Lenora A. Pluchino

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

Original language	English (US)
Pages (from-to)	108-115
Number of pages	8
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	21
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2023.0007
State	Published - Feb 2023

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2023.0007

Cite this

Saad, A., Loren, A., Bolaños-Meade, J., Chen, G., Couriel, D., Di Stasi, A., El-Jawahri, A., Elmariah, H., Farag, S., Gundabolu, K., Gutman, J., Ho, V., Hoeg, R., Horwitz, M., Hsu, J., Kassim, A., Dabaja, M. K., Magenau, J., Martin, T., ... Pluchino, L. A. (2023). Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 21(2), 108-115. https://doi.org/10.6004/jnccn.2023.0007

Saad, A, Loren, A, Bolaños-Meade, J, Chen, G, Couriel, D, Di Stasi, A, El-Jawahri, A, Elmariah, H, Farag, S, Gundabolu, K, Gutman, J, Ho, V, Hoeg, R, Horwitz, M, Hsu, J, Kassim, A, Dabaja, MK, Magenau, J, Martin, T, Mielcarek, M, Moreira, J, Nakamura, R, Nieto, Y, Ninos, C, Oliai, C, Patel, S, Randolph, B, Schroeder, M, Tzachanis, D, Varshavsky-Yanovsky, AN, Vusirikala, M, Algieri, F & Pluchino, LA 2023, 'Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 21, no. 2, pp. 108-115. https://doi.org/10.6004/jnccn.2023.0007

@article{a301ae01faee417caa9a3f23e00dfb92,

title = "Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient{\textquoteright}s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.",

author = "Ayman Saad and Alison Loren and Javier Bola{\~n}os-Meade and George Chen and Daniel Couriel and {Di Stasi}, Antonio and Areej El-Jawahri and Hany Elmariah and Sherif Farag and Krishna Gundabolu and Jonathan Gutman and Vincent Ho and Rasmus Hoeg and Mitchell Horwitz and Joe Hsu and Adetola Kassim and Dabaja, {Mohamed Kharfan} and John Magenau and Thomas Martin and Marco Mielcarek and Jonathan Moreira and Ryotaro Nakamura and Yago Nieto and Cameron Ninos and Caspian Oliai and Seema Patel and Brion Randolph and Mark Schroeder and Dimitrios Tzachanis and Varshavsky-Yanovsky, {Asya Nina} and Madhuri Vusirikala and Frankie Algieri and Pluchino, {Lenora A.}",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2023",

month = feb,

doi = "10.6004/jnccn.2023.0007",

language = "English (US)",

volume = "21",

pages = "108--115",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

AU - Saad, Ayman

AU - Loren, Alison

AU - Bolaños-Meade, Javier

AU - Chen, George

AU - Couriel, Daniel

AU - Di Stasi, Antonio

AU - El-Jawahri, Areej

AU - Elmariah, Hany

AU - Farag, Sherif

AU - Gundabolu, Krishna

AU - Gutman, Jonathan

AU - Ho, Vincent

AU - Hoeg, Rasmus

AU - Horwitz, Mitchell

AU - Hsu, Joe

AU - Kassim, Adetola

AU - Dabaja, Mohamed Kharfan

AU - Magenau, John

AU - Martin, Thomas

AU - Mielcarek, Marco

AU - Moreira, Jonathan

AU - Nakamura, Ryotaro

AU - Nieto, Yago

AU - Ninos, Cameron

AU - Oliai, Caspian

AU - Patel, Seema

AU - Randolph, Brion

AU - Schroeder, Mark

AU - Tzachanis, Dimitrios

AU - Varshavsky-Yanovsky, Asya Nina

AU - Vusirikala, Madhuri

AU - Algieri, Frankie

AU - Pluchino, Lenora A.

PY - 2023/2

Y1 - 2023/2

N2 - The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

AB - The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.

UR - http://www.scopus.com/inward/record.url?scp=85148114831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148114831&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2023.0007

DO - 10.6004/jnccn.2023.0007

M3 - Article

C2 - 36791762

AN - SCOPUS:85148114831

SN - 1540-1405

VL - 21

SP - 108

EP - 115

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this